Mount Pleasant R&D Tax Credit: Key Benefits for Businesses

R&D Tax Credits for Mount Pleasant, South Carolina Businesses

Mount Pleasant, South Carolina, thrives in industries such as healthcare, education, tourism, retail, and technology. Top companies in the city include East Cooper Medical Center, a leading healthcare provider; the College of Charleston, a major educational institution; the Patriots Point Naval & Maritime Museum, a significant tourism attraction; the Mount Pleasant Towne Centre, a key player in the retail sector; and Blackbaud, a prominent technology company. The R&D Tax Credit can provide tax savings for these industries by incentivizing innovation and technological advancements.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 4000 South Faber Place Drive, Charleston, South Carolina is less than 12 miles away from Mount Pleasant and provides R&D tax credit consulting and advisory services to Mount Pleasant and the surrounding areas suc as: Charleston, North Charleston, Summerville, Goose Creek and Hanahan.

If you have any questions or need further assistance, please call or email our local South Carolina Partner on (843) 459-7912.
Feel free to book a quick teleconference with one of our South Carolina R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Mount Pleasant, South Carolina Patent of the Year – 2024/2025

Xequel Bio Inc. has been awarded the 2024/2025 Patent of the Year for its groundbreaking ophthalmic therapeutic. Their invention, detailed in U.S. Patent No. 12138293, titled ‘Peptide formulations and ophthalmic uses thereof’, introduces a novel peptide-based eye drop designed to accelerate healing and reduce inflammation in corneal injuries.

Xequel Bio’s innovation centers on a proprietary peptide, aCT1, which modulates cellular communication to promote tissue repair. This formulation targets conditions like dry eye disease and corneal trauma, aiming to enhance patient recovery.

In early clinical studies, the eye drop demonstrated safety and tolerability, with participants showing improvements in ocular discomfort and corneal health within two weeks. The treatment works by stabilizing cell junctions, reducing harmful inflammation, and facilitating re-epithelialization of the cornea.

This advancement addresses a significant need in ophthalmology, offering a potential new therapy for patients suffering from various corneal conditions. By harnessing the body’s natural healing processes, Xequel Bio’s aCT1 technology represents a promising step forward in eye care.